LifeSci Capital initiated coverage of Kala Pharmaceuticals (KALA) with an Outperform rating and $23 price target
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KALA:
- Kala Pharmaceuticals Appoints Todd Bazemore as CEO
- Kala Bio appoints Bazemore as President, CEO, Director
- Optimistic Buy Rating for Kala Pharmaceuticals Driven by KPI-012 Trial Prospects and Financial Viability
- Kala Pharmaceuticals Reports Q2 2025 Financial Results
- Kala Pharmaceuticals reports Q2 EPS ($1.71) vs ($3.16)